MedTrace Logo

Microbiotic Analysis in Digestive Endocrine Tumors

NCT04198402 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2019-12-13

No results posted yet for this study

Summary

Incidence of digestive neuroendocrine tumors are increasing. Analysis of individual microbiota is a way to explore new neoplastic mechanisms, tumor identification and therapeutic orientations. This prospective pilot study aims to describe fecal bacterial phylogeny of patients with digestive neuroendocrine tumor.

Bacterial genomic signature will be recorded at initiation of Lanreotide treatment in naive patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or locally advanced, as well as after one year follow up.

Conditions

  • Digestive Neuroendocrine Tumor
  • Fecal Microbiota
  • Bacterial Signature

Interventions

BIOLOGICAL

Biological sampling

Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2022-01-31
Completion
2023-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04198402 on ClinicalTrials.gov